Welcome to the training session

Recast
Montelukast 4mg,5mg,10mg Tablets
 Disease Part

Asthma
Asthma is a condition in which your airways narrow and swell
and produce extra mucus. This can make breathing difficult
and trigger coughing, wheezing and shortness of breath. which
vary in severity and frequency from person to person
Asthma symptoms include:
Shortness of breath
• Chest tightness
• Pain Trouble sleeping caused by shortness of breath,
coughing or wheezing
• A whistling or wheezing sound when exhaling (wheezing is a
common sign of asthma in children)
 Types of asthma
 Exercise-induced asthma : which may be worse when the air
is cold and dry.
 Occupational asthma : triggered by workplace irritants such
as chemical fumes, gases or dust.
 Allergy-induced asthma: triggered by particular allergens,
such as pet dander, cockroaches or pollen.

Allergic Rhinitis and Asthma Have Common

Triggers
Outdoor allergens:
Pollens
Molds
Indoor allergens:
House-dust mites
Animal dander
Insects (e.g.
cockroach allergen)
Role of leukotrienes in Asthma
Leukotrienes play a key role in asthma in three ways: causing
inflammation, bronchoconstriction and mucus production. The
cysteinyl leukotrienes (LTC 4 , LTD 4 and LTE 4 ) have been
shown to be the most potent bronchconstrictors in the humans
and are believed to play a crucial role in asthmatic airway
obstruction. Leukotrienes may attract white blood cells to the
lungs, increasing swelling of the lung lining. Leukotrienes also
increase mucus production and make it easier for fluids to
accumulate (an important part of inflammation).
N.B : LTD 4 the most important cysteinyl leukotriene in the pathophysiology of asthma
because of its potent bronchoconstrictive effect (at least 200 times stronger than histamine),
causing the muscles around the airways to tighten
 Accumulation of Mucus in Airway

Short Description
Montelukast is an orally active compound that binds with high affinity and
selectively to the Cystenyl leukotrienes type-1(CysLT1) receptorand thus
inhibits both the bronchoconstrictive and inflammatory effects of the
leukotrienes.Montelukast is currently represent to first-line treatment option for
moderate to severe asthma.
 Product Part
Brand Name : Recast
Name Selection : Re from Respiratory & cast fromMontelukast
International Brand name: Singulair, Montelo-10
Dosage Form : Tablet
Generic Name : Montelukast INN
Therapeutic Class : Antiasthmatic
Strength : 4mg (Chewable tablet )
: 5mg (Chewable tablet )
: 10mg (Film Coated Tablet)
Pack size: 4mg : 30’s
Pack size: 5mg : 30’s
Price : : Competitive
Chewable Tablets:
 Pleasant Taste
 Convenient (Can be taken any time and anywhere)
 Overcome swallowing difficulties
• Better Compliance

Benefits of chewable tablets

Create a more ‘user-friendly’ experience
Eliminate need to take water with tablets
Increase compliance
Overcome swallowing difficulties
Reduce risk of esophagitis
 Mechanism of action of Recast
Asthma/ AllergenTriggers

Release of Cystenyl
leukotreine mainly from
mast cell
Recast binds to the Cys LT1
receptor

Cystenyl leukotreine binds with the Cystenyl leukotreine

receptor found in human airway

Inflammation of Inflammation of nasal

respiratory smooth mucous membrane
muscle

Bronchoconstriction Allergic rhinitis

Asthma
 Indications: Dosage & administration:

Adults (15 years of age or

- Prophylaxis
over): 10 mg once daily to
Indication
be taken in the evening.
- And chronic Children (6-14 years of
treatment of asthma. age): 5 mg once daily to be
- Relief symptoms of taken in the evening.
allergic rhinitis. Children (6 months-5
- Prevention of years of age): 4 mg once
exercise induced daily to be taken in the
bronchoconstriction. evening.
 Selling points: Target Doctor’s
• Drug of choice in the
Medicine specialist
treatment of asthma
Chest specialist
• Dosage convenience,
once daily dosing ENT specialist
• Excellent safety GPs and RMPs
profile
High risk group
Use in Pregnancy:Pregnancy category B
Use in Lactation: Montelukast should be use with
caution in nurshing women
The elderly: No special precuation is necessary
Diabetis patients Friendly
Cardiac Patients Friendly
 Market Analysis
Total Market 145,48,28,094 Growth 21.21

Product Name Company Sales Growth Unit

Montair Incepta 275,29,5159 14.61 801483

Monas Acme 238,09,3986 26.71 1222106
Provair Unimed Unihealth 15,95,154,15 16.82 441273
M-Kast Drug International 14,63,18,869 16.49 1015364
Montene Square 91,48,4502 20.33 413522
Montril ATP 66,62,4047 26.49 273552
Telukast General 63,81,9896 69.58 275850